Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature Communications
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. nature communications
  3. articles
  4. article
HTLV-1 subverts the innate immune effector gene IRF7 by viral HBZ protein for oncogenesis
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 11 May 2026

HTLV-1 subverts the innate immune effector gene IRF7 by viral HBZ protein for oncogenesis

  • Xiaoyi Yuan1,
  • Yunyun Yue2,
  • Liang Chen  ORCID: orcid.org/0009-0006-6102-85001,
  • Dongmei Liu  ORCID: orcid.org/0009-0002-2142-776X1,
  • Yi Liang1,
  • Chengcheng Lu3,
  • Sikai Yang1,
  • Zeng He1,
  • Chunxin Fan3,
  • Jing Shang1,2,
  • Masao Matsuoka  ORCID: orcid.org/0000-0002-0473-754X4 &
  • …
  • Guangyong Ma  ORCID: orcid.org/0000-0002-2003-72011,5 

Nature Communications (2026) Cite this article

  • 994 Accesses

  • Metrics details

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

Subjects

  • HTLV
  • Tumour virus infections

Abstract

Interferon regulatory factors (IRFs) are innate immune transcription factors responsible for inducing the expression of type I interferons (IFN-I), which combat pathogen invasions via initiating the downstream Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway. Among them, IRF7 plays a central role by forming heterodimers with IRF3 to initiate IFN-I production and is therefore frequently targeted by viruses to evade immune detection. Contrary to this common paradigm, we show that IRF7 is activated and upregulated by the retrovirus human T-cell leukemia virus type 1 (HTLV-1), via its oncoprotein HBZ. Moreover, IRF7 is highly expressed in HTLV-1 induced CD4 T-cell malignancy named adult T-cell leukemia/lymphoma (ATLL), and promotes the proliferation of infected cells both in vitro and in vivo. Intriguingly, HBZ is able to interfere with the interaction of IRF7 and IRF3, suppressing IFN-I pathway activation. On the other hand, IRF7 was found to upregulate and activate STAT5B, a transcription factor of the JAK-STAT pathway frequently mutated in hematological malignancies. Together, these findings reveal a mechanism by which HTLV-1 hijacks a critical innate immune effector to sustain persistent infection and drive oncogenesis without activating antiviral IFN-I pathway.

Similar content being viewed by others

Role of interferon regulatory factor 7 in corneal endothelial cells after HSV-1 infection

Article Open access 13 August 2021

Primary cells from patients with adult T cell leukemia/lymphoma depend on HTLV-1 Tax expression for NF-κB activation and survival

Article Open access 03 May 2023

LANA-specific CD4+ effector T cells accumulate at the site of KSHV infection in humanized mice

Article Open access 05 December 2025

Acknowledgements

We thank Drs. Tiejun Zhao and Xiaomin Liu for generously providing the IRF3 expression vector and the mESC-J1 cell line, respectively. G. M. discloses support for the research of this work from the National Natural Science Foundation of China (grant numbers 32270171 and 32070155), Natural Science Foundation of Hangzhou (grant number 2025SZRJJ1409) and China Pharmaceutical University (grant number 3154070031). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author information

Authors and Affiliations

  1. State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China

    Xiaoyi Yuan, Liang Chen, Dongmei Liu, Yi Liang, Sikai Yang, Zeng He, Jing Shang & Guangyong Ma

  2. School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China

    Yunyun Yue & Jing Shang

  3. Key Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai, China

    Chengcheng Lu & Chunxin Fan

  4. Department of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

    Masao Matsuoka

  5. Institute of Innovative Medicine, China Pharmaceutical University (Hangzhou), Hangzhou, China

    Guangyong Ma

Authors
  1. Xiaoyi Yuan
    View author publications

    Search author on:PubMed Google Scholar

  2. Yunyun Yue
    View author publications

    Search author on:PubMed Google Scholar

  3. Liang Chen
    View author publications

    Search author on:PubMed Google Scholar

  4. Dongmei Liu
    View author publications

    Search author on:PubMed Google Scholar

  5. Yi Liang
    View author publications

    Search author on:PubMed Google Scholar

  6. Chengcheng Lu
    View author publications

    Search author on:PubMed Google Scholar

  7. Sikai Yang
    View author publications

    Search author on:PubMed Google Scholar

  8. Zeng He
    View author publications

    Search author on:PubMed Google Scholar

  9. Chunxin Fan
    View author publications

    Search author on:PubMed Google Scholar

  10. Jing Shang
    View author publications

    Search author on:PubMed Google Scholar

  11. Masao Matsuoka
    View author publications

    Search author on:PubMed Google Scholar

  12. Guangyong Ma
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Guangyong Ma.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information (download PDF )

Reporting Summary (download PDF )

Transparent Peer Review file (download PDF )

Source data

Source Data (download XLSX )

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yuan, X., Yue, Y., Chen, L. et al. HTLV-1 subverts the innate immune effector gene IRF7 by viral HBZ protein for oncogenesis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-72980-x

Download citation

  • Received: 30 September 2025

  • Accepted: 22 April 2026

  • Published: 11 May 2026

  • DOI: https://doi.org/10.1038/s41467-026-72980-x

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Download PDF

Associated content

Collection

Cancer at Nature Portfolio

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Videos
  • Collections
  • Subjects
  • Follow us on Facebook
  • Follow us on X
  • Sign up for alerts
  • RSS feed

About the journal

  • Aims & Scope
  • Editors
  • Journal Information
  • Open Access Fees and Funding
  • Calls for Papers
  • Editorial Values Statement
  • Journal Metrics
  • Editors' Highlights
  • Contact
  • Editorial policies
  • Top Articles

Publish with us

  • For authors
  • For Reviewers
  • Language editing services
  • Open access funding
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Nature Communications (Nat Commun)

ISSN 2041-1723 (online)

nature.com footer links

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2026 Springer Nature Limited

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer